Cargando…
Proton Therapy for Prostate Cancer: Challenges and Opportunities
SIMPLE SUMMARY: Reported clinical outcomes of proton therapy (PT) for localized prostate cancer are similar to photon-based external beam radiotherapy. Apparently, the dosimetric advantages of PT have yet to be translated to clinical benefits. The suboptimal clinical outcomes of PT might be attribut...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870339/ https://www.ncbi.nlm.nih.gov/pubmed/35205673 http://dx.doi.org/10.3390/cancers14040925 |
_version_ | 1784656719072198656 |
---|---|
author | Poon, Darren M. C. Wu, Stephen Ho, Leon Cheung, Kin Yin Yu, Ben |
author_facet | Poon, Darren M. C. Wu, Stephen Ho, Leon Cheung, Kin Yin Yu, Ben |
author_sort | Poon, Darren M. C. |
collection | PubMed |
description | SIMPLE SUMMARY: Reported clinical outcomes of proton therapy (PT) for localized prostate cancer are similar to photon-based external beam radiotherapy. Apparently, the dosimetric advantages of PT have yet to be translated to clinical benefits. The suboptimal clinical outcomes of PT might be attributable to inadequate dose prescription, as indicated by the ASCENDE-RT trial. Moreover, uncertainties involved in the treatment planning and delivery processes, as well as technological limitations in PT treatment systems, may lead to discrepancies between planned doses and actual doses delivered to patients. In this article, we reviewed the current status of PT for prostate cancer and discussed different clinical implementations that could potentially improve the clinical outcome of PT for prostate cancer. Various technological advancements under which uncertainties in dose calculations can be minimized, including MRI-guided PT, dual-energy photon-counting CT and high-resolution Monte Carlo-based treatment planning systems, are highlighted. ABSTRACT: The dosimetric advantages of proton therapy (PT) treatment plans are demonstrably superior to photon-based external beam radiotherapy (EBRT) for localized prostate cancer, but the reported clinical outcomes are similar. This may be due to inadequate dose prescription, especially in high-risk disease, as indicated by the ASCENDE-RT trial. Alternatively, the lack of clinical benefits with PT may be attributable to improper dose delivery, mainly due to geometric and dosimetric uncertainties during treatment planning, as well as delivery procedures that compromise the dose conformity of treatments. Advanced high-precision PT technologies, and treatment planning and beam delivery techniques are being developed to address these uncertainties. For instance, external magnetic resonance imaging (MRI)-guided patient setup rooms are being developed to improve the accuracy of patient positioning for treatment. In-room MRI-guided patient positioning systems are also being investigated to improve the geometric accuracy of PT. Soon, high-dose rate beam delivery systems will shorten beam delivery time to within one breath hold, minimizing the effects of organ motion and patient movements. Dual-energy photon-counting computed tomography and high-resolution Monte Carlo-based treatment planning systems are available to minimize uncertainties in dose planning calculations. Advanced in-room treatment verification tools such as prompt gamma detector systems will be used to verify the depth of PT. Clinical implementation of these new technologies is expected to improve the accuracy and dose conformity of PT in the treatment of localized prostate cancers, and lead to better clinical outcomes. Improvement in dose conformity may also facilitate dose escalation, improving local control and implementation of hypofractionation treatment schemes to improve patient throughput and make PT more cost effective. |
format | Online Article Text |
id | pubmed-8870339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88703392022-02-25 Proton Therapy for Prostate Cancer: Challenges and Opportunities Poon, Darren M. C. Wu, Stephen Ho, Leon Cheung, Kin Yin Yu, Ben Cancers (Basel) Review SIMPLE SUMMARY: Reported clinical outcomes of proton therapy (PT) for localized prostate cancer are similar to photon-based external beam radiotherapy. Apparently, the dosimetric advantages of PT have yet to be translated to clinical benefits. The suboptimal clinical outcomes of PT might be attributable to inadequate dose prescription, as indicated by the ASCENDE-RT trial. Moreover, uncertainties involved in the treatment planning and delivery processes, as well as technological limitations in PT treatment systems, may lead to discrepancies between planned doses and actual doses delivered to patients. In this article, we reviewed the current status of PT for prostate cancer and discussed different clinical implementations that could potentially improve the clinical outcome of PT for prostate cancer. Various technological advancements under which uncertainties in dose calculations can be minimized, including MRI-guided PT, dual-energy photon-counting CT and high-resolution Monte Carlo-based treatment planning systems, are highlighted. ABSTRACT: The dosimetric advantages of proton therapy (PT) treatment plans are demonstrably superior to photon-based external beam radiotherapy (EBRT) for localized prostate cancer, but the reported clinical outcomes are similar. This may be due to inadequate dose prescription, especially in high-risk disease, as indicated by the ASCENDE-RT trial. Alternatively, the lack of clinical benefits with PT may be attributable to improper dose delivery, mainly due to geometric and dosimetric uncertainties during treatment planning, as well as delivery procedures that compromise the dose conformity of treatments. Advanced high-precision PT technologies, and treatment planning and beam delivery techniques are being developed to address these uncertainties. For instance, external magnetic resonance imaging (MRI)-guided patient setup rooms are being developed to improve the accuracy of patient positioning for treatment. In-room MRI-guided patient positioning systems are also being investigated to improve the geometric accuracy of PT. Soon, high-dose rate beam delivery systems will shorten beam delivery time to within one breath hold, minimizing the effects of organ motion and patient movements. Dual-energy photon-counting computed tomography and high-resolution Monte Carlo-based treatment planning systems are available to minimize uncertainties in dose planning calculations. Advanced in-room treatment verification tools such as prompt gamma detector systems will be used to verify the depth of PT. Clinical implementation of these new technologies is expected to improve the accuracy and dose conformity of PT in the treatment of localized prostate cancers, and lead to better clinical outcomes. Improvement in dose conformity may also facilitate dose escalation, improving local control and implementation of hypofractionation treatment schemes to improve patient throughput and make PT more cost effective. MDPI 2022-02-13 /pmc/articles/PMC8870339/ /pubmed/35205673 http://dx.doi.org/10.3390/cancers14040925 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Poon, Darren M. C. Wu, Stephen Ho, Leon Cheung, Kin Yin Yu, Ben Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title | Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title_full | Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title_fullStr | Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title_full_unstemmed | Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title_short | Proton Therapy for Prostate Cancer: Challenges and Opportunities |
title_sort | proton therapy for prostate cancer: challenges and opportunities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870339/ https://www.ncbi.nlm.nih.gov/pubmed/35205673 http://dx.doi.org/10.3390/cancers14040925 |
work_keys_str_mv | AT poondarrenmc protontherapyforprostatecancerchallengesandopportunities AT wustephen protontherapyforprostatecancerchallengesandopportunities AT holeon protontherapyforprostatecancerchallengesandopportunities AT cheungkinyin protontherapyforprostatecancerchallengesandopportunities AT yuben protontherapyforprostatecancerchallengesandopportunities |